Amgen (AMGN) reported Q4 non-GAAP earnings late Wednesday of $5.31 per diluted share, up from $4.71 a year ago.
Analysts polled by FactSet expected $5.08.
Revenue for the quarter that ended Dec. 31 was $9.09 billion compared with $8.20 billion a year ago.
Analysts expected $8.88 billion.
For 2025, the biotech company is projecting non-GAAP EPS of $20.00 to $21.20 on revenue of $34.3 billion to $35.7 billion.
Analysts are looking for $20.92 and $34.62 billion, respectively.
Amgen shares were declining 2% in after-market activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.